Healthcare Industry News: Onset Therapeutics
News Release - July 27, 2009
Onset Therapeutics Announces Additions to Senior Management TeamCUMBERLAND, R.I.--(HSMN NewsFeed)--Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced two key additions to its Senior Management Team. Doug Abel has joined the company in the role of General Manager and Sheila Kennedy will serve as Vice President of Marketing.
With the addition of these two experienced and accomplished commercial leaders in the field of dermatology, Onset Therapeutics continues to invest in its commercial infrastructure to enhance the growth of its existing commercial products and prepare for product launches which will further strengthen the Company’s dermatologic product portfolio. Doug and Sheila bring over 20 years of combined dermatology experience to the organization.
Doug Abel – General Manager
Doug is an experienced dermatology and specialty pharmaceutical leader who has helped build a number of organizations. He brings more than 22 years of specialty pharmaceutical experience and has spent 14 years within dermatology. Prior to joining Onset Therapeutics, Doug served as the CEO of two pre-commercial, dermatology based organizations. Doug also built and led the dermatology team at Biogen Idec for 4 years, and was responsible for all aspects of commercial development as well as for managing the dermatology division. Prior to joining Biogen, Doug spent 12 years at Allergan, where his roles included Director of Marketing - BOTOX®, Senior Product Manager in Allergan's skin care division, National Accounts Manager, BOTOX® Medical Consultant, District Manager, and Sales Representative. In addition to his broad dermatology experience, Doug brings a tremendous amount of leadership and organizational development skills.
Sheila Kennedy – Vice President of Marketing
Sheila brings 16 years of marketing and sales experience to Onset Therapeutics and has held a variety of positions in dermatology marketing over the last 6 years, including serving as a consultant to companies developing and expanding commercial operations in dermatology. Sheila led the marketing effort at CollaGenex Pharmaceuticals as the company entered the dermatology market in 2003, and was instrumental in the launch of Oracea®, the leading systemic treatment used for rosacea. CollaGenex was acquired by Galderma for $420 million in 2008. During her career, Sheila has also held marketing, market research, and sales positions with AstraZeneca and AstraMerck.
“I am pleased to announce these additions to our senior leadership team, as they will be essential to ensuring the continued growth and success of our rapidly expanding commercial organization,” stated Michael Heffernan, President of Onset Therapeutics. “With this experienced team in place, Onset is poised to build on our current dermatological product line and maximize the multiple novel products that we currently have in development.”
About Onset Therapeutics
Onset Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of dermatology products formulated with the Company’s innovative proprietary topical formulation technologies and unique delivery systems. The Company utilizes its novel DELEVO(TM) Foam Technology that is designed to deliver enhanced penetration of proven active ingredients in cosmetically elegant, hydrating formulations with the goal of enhancing patient compliance. Onset Therapeutics is a wholly owned subsidiary of Collegium Pharmaceutical (www.collegiumpharma.com).
For more information, please visit the company’s website at www.onsettx.com.
Source: Onset Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.